CorMedix (CRMD) to Post Earnings on Thursday

Posted by Brian Himes on Jul 30th, 2026

CorMedix (NASDAQ:CRMD – Get Free Report) is projected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of $0.26 per share and revenue of $96.04 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.

CorMedix (NASDAQ:CRMD – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.35 by $0.08. The firm had revenue of $127.43 million for the quarter, compared to the consensus estimate of $104.96 million. CorMedix had a net margin of 45.25% and a return on equity of 45.57%. The business’s revenue was up 226.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.30 earnings per share. On average, analysts expect CorMedix to post $1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CorMedix Trading Down 2.2%

Shares of CorMedix stock opened at $7.19 on Thursday. The firm has a market capitalization of $564.06 million, a PE ratio of 3.38 and a beta of 1.48. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.97 and a quick ratio of 2.74. The company’s fifty day moving average price is $8.33 and its two-hundred day moving average price is $7.62. CorMedix has a 52-week low of $6.13 and a 52-week high of $14.96.

Analyst Ratings Changes

Several analysts have recently weighed in on CRMD shares. Needham & Company LLC lifted their target price on shares of CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Citizens Jmp reissued a “market outperform” rating and issued a $19.00 price target on shares of CorMedix in a research report on Tuesday, April 28th. D. Boral Capital reissued a “buy” rating and issued a $14.00 price target on shares of CorMedix in a research report on Monday, April 27th. Zacks Research upgraded shares of CorMedix from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Leerink Partners lifted their price objective on CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a report on Tuesday, April 28th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $14.86.

Get Our Latest Research Report on CRMD

Institutional Investors Weigh In On CorMedix

Several large investors have recently made changes to their positions in CRMD. Deerfield Management Company L.P. acquired a new stake in shares of CorMedix during the 3rd quarter worth about $38,656,000. Marshall Wace LLP lifted its holdings in CorMedix by 34.6% during the 3rd quarter. Marshall Wace LLP now owns 3,473,494 shares of the company’s stock valued at $40,397,000 after purchasing an additional 893,518 shares during the last quarter. UBS Group AG boosted its position in CorMedix by 295.3% in the third quarter. UBS Group AG now owns 1,090,908 shares of the company’s stock valued at $12,687,000 after buying an additional 814,964 shares in the last quarter. Jump Financial LLC acquired a new position in CorMedix in the third quarter valued at about $9,003,000. Finally, Goldman Sachs Group Inc. boosted its position in CorMedix by 259.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 828,781 shares of the company’s stock valued at $9,639,000 after buying an additional 597,971 shares in the last quarter. Institutional investors own 34.18% of the company’s stock.

CorMedix Company Profile

(Get Free Report)

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.